A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
Jing‐Jing Li(Shanghai Institute of Nutrition and Health), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xu(China Jiliang University), Qing Wei(Zhejiang Cancer Hospital), Fabiao Zhang(Wenzhou Medical University), Cong Luo(Huazhong University of Science and Technology), Zhe Han(University of Maryland, Baltimore)
Cited by 7
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption
|Journal of Clinical Investigation|2013|341